PanGen Biotech Inc Cash Flow-to-Debt Ratio
PanGen Biotech Inc cash flow-to-debt ratio. PanGen Biotech Inc (222110) has a Cash Flow-to-Debt Ratio of -1.34x as of September 2025, meaning its operating cash flow of ₩-3.66 Billion could theoretically repay -1% of its total liabilities (₩2.74 Billion) in one year. Check 222110 cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of PanGen Biotech Inc (2014–2024)
Cash flow-to-debt ratio of PanGen Biotech Inc from 2014 to 2024. Historical debt coverage capacity for PanGen Biotech Inc across 11 annual periods. Check PanGen Biotech Inc total reinvestment intensity to assess the company's total reinvestment commitment from operating cash flow.
PanGen Biotech Inc Cash Flow-to-Debt Ratio by Year (2014–2024)
PanGen Biotech Inc cash flow-to-debt ratio by year from 2014 to 2024. Year-by-year debt coverage analysis for PanGen Biotech Inc. For the full cash flow conversion analysis, see PanGen Biotech Inc (222110) cash conversion ratio.
| Year | CF-to-Debt Ratio | Operating CF (KRW) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | 0.53x | ₩2.99 Billion | ₩5.64 Billion | ▲ +225.6% |
| 2023 | -0.42x | ₩-3.45 Billion | ₩8.18 Billion | ▲ +58.4% |
| 2022 | -1.01x | ₩-3.50 Billion | ₩3.45 Billion | ▼ -576.6% |
| 2021 | -0.15x | ₩-3.32 Billion | ₩22.18 Billion | ▲ +29.2% |
| 2020 | -0.21x | ₩-4.68 Billion | ₩22.10 Billion | ▼ -19.5% |
| 2019 | -0.18x | ₩-3.66 Billion | ₩20.66 Billion | ▲ +41.0% |
| 2018 | -0.30x | ₩-5.61 Billion | ₩18.67 Billion | ▼ -95.7% |
| 2017 | -0.15x | ₩-657.84 Million | ₩4.28 Billion | ▲ +92.6% |
| 2016 | -2.08x | ₩-4.35 Billion | ₩2.09 Billion | ▼ -1107.5% |
| 2015 | -0.17x | ₩-1.61 Billion | ₩9.34 Billion | ▲ +20.6% |
| 2014 | -0.22x | ₩-1.34 Billion | ₩6.18 Billion | — |